Mastering the Double-Bottom Pattern (Unveiling 3 Intriguing Setups in Today's Market)Zacks Investment Research • 06/07/23
Biogen Rises As 'Relatively Benign' FDA Documents Suggest An Alzheimer's Approval Is NearInvestors Business Daily • 06/07/23
Biogen Hits Buy Zone On A Fresh Win In Alzheimer's Disease; Eli Lilly, Eisai Shares JumpInvestors Business Daily • 06/01/23
Biogen Inc. (BIIB) Up 4.7% Since Last Earnings Report: Can It Continue?Zacks Investment Research • 05/25/23
1 Major Advantage Biogen May Have Over Pharma Giant Eli Lilly in a Multibillion-Dollar MarketThe Motley Fool • 05/19/23
Health Canada Accepts New Drug Submission for Lecanemab as Treatment for Early Alzheimer's DiseaseGlobeNewsWire • 05/15/23
Eli Lilly Surges After Alzheimer's Treatment Succeeds; Biogen Also RisesInvestors Business Daily • 05/03/23
Alzheimer's patients may wait years to get treated with new drugs, putting them at risk of more severe diseaseCNBC • 04/30/23
FDA Grants Accelerated Approval for QALSODY™ (tofersen) for SOD1-ALS, a Major Scientific Advancement as the First Treatment to Target a Genetic Cause of ALSGlobeNewsWire • 04/25/23
Biogen isn't concerned about competing with Eli Lilly in the Alzheimer's drug space, CEO saysCNBC • 04/25/23
FDA grants accelerated approval for Biogen ALS drug that treats rare form of the diseaseCNBC • 04/25/23